As monotherapy for the first-line treatment of patients with NSCLC whose tumors have high PD-L1 expression (Tumor Proportion Score ≥50%), with no EGFR, ALK or ROS1 aberrations, and disease that is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.